Laura van ‘t Veer, PhD, is the Angela and Shu Kai Chan Endowed Chair in Cancer Research and is a Professor of Laboratory Medicine at UCSF. She is also the Program Co-Leader of the UCSF Helen Diller Family Comprehensive Cancer Center Breast Oncology Program (BOP), Director of Applied Genomics with the UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF-Site Principal Investigator of the Athena Breast Health Network. Dr. van ‘t Veer is a world renowned Molecular Biologist and inventor of MammaPrint®. Her research focuses on personalized medicine, to advance patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. Dr. van 't Veer is the lead scientist of the 6693 patient MINDACT trial which showed that for early diagnosed breast cancer, 46% of clinically high risk patients can safely forgo chemotherapy (New England Journal of Medicine 2016). MammaPrint® is included in several international and national guidelines for breast cancer management. Dr. van ‘t Veer is the Biomarker Committee Chair for the multicenter adaptive breast cancer clinical trial I-SPY 2, overseeing the FDA-IDE ‘Response-Predictive-Subtyping’ companion diagnostics processes. She served as board member for the AACR 2011-2014, and is currently the chair of AACR Diagnostics Policy Sub-Committee, part of the AACR Science Policy and Government Affairs Committee. She received the 2017 European Cancer Organization Clinical Research Award, in 2015 the European Inventor Award in the category Small and Medium-sized Enterprises (European Patent Office), in 2014 the second prize EU Women Innovator Award (European Commission), and in 2007 the European Society of Medical Oncology (ESMO) Lifetime Achievement Award. In 2020 she received the Precision Medicine World Conference Luminary award and in 2020 the Giants Of Cancer Care Award for Diagnostics.